Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
basal insulin
Pharma
Novo's long-lasting insulin candidate matches Lantus in phase 2
Novo Nordisk is working on drugs that can keep people off insulin—but that doesn't mean it isn't working to improve insulin options, too.
Carly Helfand
Jun 14, 2020 6:55pm
Sanofi's Toujeo tops Tresiba in tough-to-treat diabetes group
Jun 10, 2019 11:05am
Novo’s oral semaglutide could disrupt diabetes coverage: analyst
Mar 5, 2019 12:05pm
Mylan, Biocon inch closer to Lantus copycat launch
Dec 13, 2018 11:07am
Lousy basal insulin market prompts Merck to ditch Lantus biosim
Oct 12, 2018 11:03am
Sanofi taps insider Stefan Oelrich to liven up diabetes biz
Oct 3, 2017 4:40am